Since TRPM7 is the first druggable target in HCC, the development of novel NS8593-like compounds that are able to inhibit the TRPM7 channel, increase MRTF-A nuclear export, and thereby decrease SRF transcriptional activity is of utmost importance. The gene discussed is MRTFA; the disease is hepatocellular carcinoma.